Piracetam
- Atc Codes:N06BX03
- CAS Codes:7491-74-9
- PHARMGKB ID:7491-74-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
Brand Names
Europe
Austria: Cerebryl, Nootropil, Novocephal, Pirabene; Belgium: Braintop, Docpirace, Geratam, Noodis Nootropil, Piracemed, Piracetam, Piracetop; Bulgaria: Nootropil, Piracebral, Piracetam, Pyramen, Pyraminol; Czech Republic: Geratam, Nootropil, Oikamid, Pirabene, Piracetam; Estonia: Nootropil; Finland: Nootropil; France: Gabacet, Nootropyl, Piracetam; Germany: Cebrotonin, Cerepar, Cuxabrain, Nootrop, Nootropil, Normabrain, Piracebral, Piracetam, Piracetrop, Psygeriat; Greece: Aminotrophylle, Arterosol, Cebragil, Celebral, Centracetam, Cetrop, Cosmoxim, Espritam, Latys, Lobelo, Logofren, Lowtens, Lyoathiran, Meclivin, Meditam, Noforit, Nootrop, Oxynium, Picetamyl, Piracem, Piracetam, Pitament, Psycoton, Stamin, Unlockazin, Zalipan; Hungary: Cerebryl, Lucetam, Memoril, Nootropil, Pirabene, Piracetam; Ireland: Nootropil; Italy: Nootropil, Piracetam, Psycoton; Lithuania: Nootropil, Piracetam, Piracetamas, Piracetams; Luxembourg: Braintop, Docpirace, Geratam, Noodis, Nootropil, Piracetam, Piracetop; Netherlands: Nootropil, Piracetam; Poland: Biotropil, Lucetam, Memotropil, Nootropil; Portugal: Acetar, Noostan, Oxibran, Piracetam; Romania: Lucetam, Memotal, Neuristim, Nootropil, Piracetam; Slovakia: Kalicor, Lucetam, Oikamid, Pirabene, Piracetam; Slovenia: Nootropil; Spain: Ciclofalina, Nootropil; Sweden: Nootropil; UK: Nootropil.
Latin America
Argentina: Noostan; Brazil: Citilan, Nootron, Nootropil; Mexico: Nootropil.
Asia
Japan: Myocalm.
Drug combinations
Chemistry
Piracetam: C~6~H~10~N~2~O~2.~ Mw: 142.16. 1-Pyrrolidineacetamide, 2-oxo-. CAS-7491-74-9.
Pharmacologic Category
Anti-Dementia Agents; Nootropics. (ATC-Code: N06BX03).
Mechanism of action
Facilitates long-term potentiation, increases neurotransmitter release from presynaptic terminals and increases amount of neurotransmitter, particularly acetylcholine, in brain, but does not act directly on choline transport or metabolism.
Therapeutic use
Treatment of attention and memory disorders. Adjunctive treatment of cortical myoclonus.
Pregnancy and lactiation implications
There are no adequate studies in pregnant women. Crosses placenta. Use only if benefit outweighs risk. Avoid use in nursing women (excreted in breast milk).
Unlabeled use
Contraindications
Hypersensitivity to piracetam or any derivatives of pirrolidone. Cerebral hemorrhage. Hepatic/renal impairment. Pregnancy and breast-feeding.
Warnings and precautions
Avoid abrupt withdrawal. Use caution in the elderly. Hemostasis, major surgery, or severe hemorrhage. Renal impairment (avoid if CrCl <20 mL/minute).